Akebia Therapeutics, Inc. (AKBA) News
Filter AKBA News Items
AKBA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AKBA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AKBA News From Around the Web
Below are the latest news stories about AKEBIA THERAPEUTICS INC that investors may wish to consider to help them evaluate AKBA as an investment opportunity.
New Strong Sell Stocks for January 3rdAKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024. |
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on December 31, 2024. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
High Growth Tech Stocks To Watch In December 2024Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility. |
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five yearsAkebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders will doubtless be very grateful to see the share price up 31% in... |
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST. Among other business updates, Mr. Butler will discuss the Vafseo® (vadadustat) U.S. launch. |
New Strong Sell Stocks for December 5thAKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024. |
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on DialysisAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo® (vadadustat) Outcomes In-Center Experience (VOICE) collaborative trial. Akebia announced the collaborative trial initiation in September 2024. |
New Strong Sell Stocks for November 27thAKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024. |
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 10:30 AM EST. |
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney DiseaseAkebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three time |